January 16, 2025

Trastuzumab/Pertuzumab vs Cetuximab/Irinotecan in RAS/BRAF Wild-Type HER2-Positive Metastatic Colorectal Cancer

In a phase II trial (S1613) reported in Journal of Clinical Oncology, Raghav et al found no difference in progression-free survival overall with trastuzumab/pertuzumab vs cetuximab/irinotecan in secon...

The ASCO Post

January 13, 2025

Medicare Advantage vs Traditional Medicare: Cost Differences in Cancer Drugs

Are patients enrolled in Medicare Advantage more or less likely to be prescribed high-cost drugs for cancer treatment compared with traditional Medicare? A new study investigated.

The ASCO Post

January 06, 2025

Trends in Early-Onset Colorectal Cancer

As reported in The Lancet Oncology by Sung et al, analysis of international population–based cancer registry data indicate an increase in the incidence of colorectal cancer among younger persons (age ...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

December 23, 2024

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer

On December 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to encorafenib (Braftovi) in combination with cetuximab and modified fluorouracil, leucovorin, and oxaliplatin ...

The ASCO Post

February 15, 2024

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Circulating tumor DNA may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from receiving adjuvant chemotherapy. The re...

The ASCO Post

June 23, 2023

Expert Point of View: Lisa Newman, MD, MPH, FACS, FASCO

Dr. Lisa Newman emphasizes the critical relevance of including diverse populations in clinical genomic profiling for colorectal cancer, shedding light on potential missed opportunities in homogeneous population studies.

The ASCO Post

August 02, 2023

Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors

About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent st...

The ASCO Post

December 04, 2023

Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors

Researchers investigated whether the regular consumption of navy beans could help improve the gut microbiome of colorectal cancer survivors.

The ASCO Post